

**The NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee:** J. Ansite, A.N. Balamurugan, B. Barbaro, J. Battle, D. Brandhorst, J. Cano, X. Chen, S. Deng, D. Feddersen, A. Friberg, T. Gilmore, J.S. Goldstein, E. Holbrook, A. Khan, T. Kin, J. Lei, E. Linetsky, C. Liu, X. Luo, K. McElvaney, Z. Min, J. Moreno, D. O’Gorman, K.K. Papas, G. Putz, C. Ricordi, G. Szot, T. Templeton, L. Wang, J.J. Wilhelm, J. Willits, T. Wilson, X. Zhang

**The NIH CIT Consortium**

**Emory University:** J. Avila, B. Begley, J. Cano, S. Carpentier, E. Holbrook, J. Hutchinson, C.P. Larsen, J. Moreno, M. Sears, N.A. Turgeon, D. Webster

**Massachusetts General Hospital:** S. Deng, J. Lei, J.F. Markmann

**NIAID:** N.D. Bridges, C.W. Czarniecki, J.S. Goldstein, G. Putz, T. Templeton, T. Wilson

**NIDDK:** T.L. Eggerman

**Northwestern University:** P. Al-saden, J. Battle, X. Chen, A. Hecyk, H. Kissler, X. Luo, M. Molitch, N. Monson, E. Stuart, A. Wallia, L. Wang, S. Wang, X. Zhang

**University of Alberta, Edmonton:** D. Bigam, P. Campbell, P. Dinyari, T. Kin, N. Kneteman, J. Lyon, A. Malcolm, D. O’Gorman, C. Onderka, R. Owen, R. Pawlick, B. Richer, S. Rosichuk, D. Sarman, A. Schroeder, P.A. Senior, A.M.J. Shapiro, L. Toth, V. Toth, W. Zhai

**University of California–San Francisco:** K. Johnson, J. McElroy, A.M. Posselt, M. Ramos, T. Rojas, P.G. Stock, G. Szot

**University of Illinois, Chicago:** B. Barbaro, J. Martellotto, J. Oberholzer, M. Qi, Y. Wang

**University of Iowa (Data Coordinating Center):** L. Bayman, K. Chaloner, W. Clarke, J.S. Dillon, C. Diltz, G.C. Doelle, D. Ecklund, D. Feddersen, E. Foster, L. G. Hunsicker, C. Jaspersen, D-E Lafontant, K. McElvaney, T. Neill-Hudson, D. Nollen, J. Qidwai, H. Riss, T. Schwieger, J. Willits, J. Yankey

**University of Miami:** R. Alejandro, A.C. Corrales, R. Faradji, T. Froud, A.A. Garcia, E. Herrada, H. Ichii, L. Inverardi, N. Kenyon, A. Khan, E. Linetsky, J. Montelongo, E. Peixoto, K. Peterson, C. Ricordi, J. Szust, X. Wang

**University of Minnesota:** M.H. Abdulla, J. Ansite, A.N. Balamurugan, M.D. Bellin, M. Brandenburg, T. Gilmore, J. V. Harmon, B.J. Hering, R. Kandaswamy, G. Loganathan, K. Mueller, K.K. Papas, J. Pedersen, J.J. Wilhelm, J. Witson

**University of Pennsylvania:** C. Dalton-Bakes, H. Fu, M. Kamoun, J. Kearns, Y. Li, C. Liu, E. Luning-Prak, Y. Luo, E. Markmann, Z. Min, A. Naji, M. Palanjian, M. Rickels, R. Shlansky-Goldberg, K. Vivek, A.S. Ziaie

**University of Wisconsin:** L. Fernandez, D.B. Kaufman, L. Zitur

**Uppsala University:** D. Brandhorst, A. Friberg, O. Korsgren

*Supported by grants from the National Institute of Allergy and Infectious Diseases and the National Institute for Diabetes and Digestive and Kidney Diseases.*

- At Emory University, U01AI089317.
- At Northwestern University, U01AI089316.
- At the University of Alberta, Edmonton: U01AI065191.
- At the University of California, San Francisco, U01DK085531.
- At the University of Illinois, Chicago, 5U01DK070431-10.
- At the University of Iowa, U01DK070431.
- At the University of Miami, U01DK070460.
- At the University of Minnesota, U01AI065193.
- At the University of Pennsylvania, U01DK070430.
- At Uppsala University, U01AI065192.

*In addition, the study was supported by the following GCRC and CTSA awards:*

- At Emory University: UL1TR000454.
- At Northwestern University: 5UL1RR025741 and 8UL1TR000150.
- At the University of California, San Francisco, UL1TR000004.
- At the University of Illinois, Chicago, UL1TR000050.
- At the University of Miami: 1UL1TR000460.
- At the University of Minnesota: 5M01-RR000400 and UL1TR000114.
- At the University of Pennsylvania: UL1TR000003.

Address correspondence to: Camillo Ricordi MD, Chairman, CIT Steering Committee, [ricordi@miami.edu](mailto:ricordi@miami.edu)

## To cite this article

*Raw Material Specification, Insulin-like Growth Factor-1 (IGF-1) – Standard Operating Procedure of the NIH Clinical Islet Transplantation Consortium*

CellR4 2016; 4 (3): e1920

**DAIT, NIAID, NIH**

**SOP  
APPENDIX**



**Document No.**  
SOP 3102, A12

**Revision No.**  
00

**Effective Date**  
07 July 2008

**Supersedes Date**  
NA

Page 1 of 1

**Document Title:**

**RAW MATERIAL SPECIFICATION,  
INSULIN-LIKE GROWTH FACTOR-1 (IGF-1)**

**1.0 Requirements:**

TEST	METHOD	REQUIREMENT
<b>Identity</b>	Visual Inspection	Container label and Certificate of Analysis must specify: "Insulin-like Growth Factor-1," or "IGF-1," "1.0 mg/vial," and must have same lot number.
<b>Vendor</b>	Visual Inspection	Cell Sciences, Cat. #CM001
<b>Review of Vendor's Certificate of Analysis</b>	Visual Inspection	All requirements on the Certificate of Analysis must be met. Appearance: White Powder Molecular Weight: 7649 daltons by mass spectrometry Biological Activity: ED <sub>50</sub> ≤30 ng/mL N-terminal Sequence: 5 Residues Endotoxin (LAL): < 0.1 EU/μg Purity (HPLC): > 95% The Certificate of Analysis must be signed and dated.

**2.0 Storage**

2°C to 4°C

**Reconstitution and Stock Solutions:** The peptide should be reconstituted in 10 mM HCl at a concentration of 1 mg/mL. In this form it is stable for at least 3 months at -20°C or -80°C. Avoid freeze-thaw cycles.

**IMPORTANT:** Irrespective of size, always reconstitute the entire vial in situ and then aliquot. Each vial contains the net amount of peptide indicated on the label but ~15 – 20 % more by mass due to the residual moisture retained through the freeze drying process. **DO NOT** estimate peptide content by weight or gravimetric means as this will underestimate the actual peptide content by ~15 – 20 %.

**3.0 Formulation:**

NA